AggreSure ß-Amyloid (1-42), human – 0.25 mg

Overview

AggreSure ß-Amyloid (1-42), a human peptide, is essential for research focused on Alzheimer’s Disease. This peptide has been pretreated and rigorously tested for aggregation using the SensoLyte® ThT Aß42 Aggregation kit (Cat# AS-72214), ensuring your experiments yield reliable, reproducible results. As Alzheimer’s Disease (AD) remains the most prevalent neurodegenerative disorder affecting the elderly, understanding the role of ß-Amyloid in its pathology is critical. With a net quantity of 0.25 mg, AggreSure ß-Amyloid (1-42) allows you to investigate the aggregation phenomena that leads to the formation of senile plaques and neurofibrillary tangles in vital brain regions.

Key Features

• Pretested for aggregation using SensoLyte® ThT Aß42 Aggregation kit
• Guaranteed aggregation, ensuring experimental reliability
• Net quantity of 0.25 mg, suitable for various research applications
• Focus on Alzheimer’s Disease, enhancing understanding of its biological mechanisms

Specifications

FAQ

What is the significance of ß-Amyloid (1-42) in Alzheimer’s research?

ß-Amyloid (1-42) is a key peptide that contributes to the formation of plaques in the brains of Alzheimer’s patients, making it crucial for understanding disease mechanisms and developing therapeutic strategies.

How is AggreSure ß-Amyloid (1-42) tested for aggregation?

Our AggreSure ß-Amyloid (1-42) undergoes testing using the SensoLyte® ThT Aß42 Aggregation kit, which ensures high reliability and consistency in research results.

Can I find other related peptides for my research?

Absolutely! You can explore our extensive collection of peptides tailored for various applications, including our Autocamtide-2 and CREBtideboth valuable for neurological research.

Related Products

• PKG Substrate [RKRSRAE], Glasstide